Fig. 4: anlotinib can inhibit endothelial PD-L1 expression via the AKT pathway. | Cell Death & Disease

Fig. 4: anlotinib can inhibit endothelial PD-L1 expression via the AKT pathway.

From: anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

Fig. 4

a Western blot analysis showed p-AKT and p-ERK levels in with- or without-anlotinib (0.1 µm) treated HUVECs at the indicated time points. b Western blot analysis showed PD-L1 expression levels in HUVECs treated by U0126 (ERK inhibitor,10 µm), Ly294002 (AKT inhibitor, 10 µm), or anlotinib (0.1 µm) at 24 h. c, e Western blot analysis showed p-AKT and PD-L1 expression in MRMEC and bEnd.3 treated as shown. d, f Western blot analysis showed p-AKT and PD-L1 expression in HUVECs treated as shown. (SC-79, one of activator of AKT). Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, Student’s t test.

Back to article page